



SERES
THERAPEUTICS™

Seres Therapeutics to Present at Goldman Sachs 37th Annual Global Healthcare Conference

June 2, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 2, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced it will present at the Goldman Sachs 37th Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 7 at 9:20 a.m. PT.

Live audio webcast will be available under the Investors and Media section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. Seres' most advanced program, SER-109, has successfully completed a Phase 1b/2 study demonstrating a clinical benefit in patients with recurring *Clostridium difficile* infection (CDI) and is currently being evaluated in a Phase 2 study in recurring CDI. The FDA has granted SER-109 Orphan Drug, as well as Breakthrough Therapy, designations. Seres' second clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis (UC). For more information, please visit www.serestherapeutics.com. Follow us on Twitter @SeresTx.



View source version on businesswire.com: <http://www.businesswire.com/news/home/20160602005694/en/>

Source: Seres Therapeutics

IR and PR Contact:

Seres Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor Relations and Corporate Communications
Ctanzi@serestherapeutics.com